LU85854A1 - Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1,2,4-triazole-3-carboxamide - Google Patents

Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1,2,4-triazole-3-carboxamide Download PDF

Info

Publication number: LU85854A1
Authority: LU; Luxembourg
Prior art keywords: compound; viral diseases; caused; composition; medical treatment
Prior art date: 1984-10-29

Application number

LU85854A

Other languages

English (en)

French (fr)

Inventor

Roberts Angus Smith

Humberto Fernandez

Original Assignee

Vira Tek Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-10-29

Filing date

1985-04-17

Publication date

1985-12-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24673430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU85854(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1985-04-17 Application filed by Vira Tek Inc filed Critical Vira Tek Inc

1985-12-16 Publication of LU85854A1 publication Critical patent/LU85854A1/fr

Links

201000010099 disease Diseases 0.000 title claims abstract description 45
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 45
230000003612 virological effect Effects 0.000 title claims abstract description 35
238000011282 treatment Methods 0.000 title claims abstract description 33
238000000034 method Methods 0.000 title claims description 23
150000001875 compounds Chemical class 0.000 claims abstract description 29
241000700605 Viruses Species 0.000 claims abstract description 27
241000725643 Respiratory syncytial virus Species 0.000 claims abstract description 24
241000712891 Arenavirus Species 0.000 claims abstract description 12
241001430294 unidentified retrovirus Species 0.000 claims abstract description 7
241000713112 Orthobunyavirus Species 0.000 claims abstract 2
241000282412 Homo Species 0.000 claims description 13
239000000443 aerosol Substances 0.000 claims description 9
230000001154 acute effect Effects 0.000 claims description 8
208000011580 syndromic disease Diseases 0.000 claims description 8
206010061598 Immunodeficiency Diseases 0.000 claims description 6
239000003814 drug Substances 0.000 claims description 6
230000000241 respiratory effect Effects 0.000 claims description 6
210000002345 respiratory system Anatomy 0.000 claims description 6
206010059866 Drug resistance Diseases 0.000 claims description 5
239000003443 antiviral agent Substances 0.000 claims description 5
229940079593 drug Drugs 0.000 claims description 5
238000002347 injection Methods 0.000 claims description 4
239000007924 injection Substances 0.000 claims description 4
238000001990 intravenous administration Methods 0.000 claims description 4
208000002330 Congenital Heart Defects Diseases 0.000 claims description 3
208000019693 Lung disease Diseases 0.000 claims description 3
208000028831 congenital heart disease Diseases 0.000 claims description 3
230000000699 topical effect Effects 0.000 claims description 3
239000000203 mixture Substances 0.000 claims 10
230000007812 deficiency Effects 0.000 claims 4
238000004519 manufacturing process Methods 0.000 claims 4
239000004480 active ingredient Substances 0.000 claims 2
239000008194 pharmaceutical composition Substances 0.000 claims 2
SJCDBQHCQSIZHN-UHFFFAOYSA-N 1,2-dihydrotriazole-3-carboxamide Chemical compound NC(=O)N1NNC=C1 SJCDBQHCQSIZHN-UHFFFAOYSA-N 0.000 claims 1
238000011200 topical administration Methods 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 7
239000002831 pharmacologic agent Substances 0.000 abstract description 4
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 34
229960000329 ribavirin Drugs 0.000 description 29
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 28
208000032982 Hemorrhagic Fever with Renal Syndrome Diseases 0.000 description 14
208000016028 Korean hemorrhagic fever Diseases 0.000 description 11
241001465754 Metazoa Species 0.000 description 10
206010023927 Lassa fever Diseases 0.000 description 9
208000015181 infectious disease Diseases 0.000 description 9
241001493065 dsRNA viruses Species 0.000 description 7
238000012360 testing method Methods 0.000 description 7
206010061192 Haemorrhagic fever Diseases 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
208000030507 AIDS Diseases 0.000 description 5
241000712003 Human respirovirus 3 Species 0.000 description 5
206010035664 Pneumonia Diseases 0.000 description 5
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
239000002245 particle Substances 0.000 description 5
239000000902 placebo Substances 0.000 description 5
229940068196 placebo Drugs 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
206010010099 Combined immunodeficiency Diseases 0.000 description 4
102100034343 Integrase Human genes 0.000 description 4
206010037660 Pyrexia Diseases 0.000 description 4
206010006448 Bronchiolitis Diseases 0.000 description 3
206010011224 Cough Diseases 0.000 description 3
241000150562 Hantaan orthohantavirus Species 0.000 description 3
206010035742 Pneumonitis Diseases 0.000 description 3
206010058874 Viraemia Diseases 0.000 description 3
208000036142 Viral infection Diseases 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
230000001900 immune effect Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
210000004072 lung Anatomy 0.000 description 3
239000006199 nebulizer Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
230000009385 viral infection Effects 0.000 description 3
206010009192 Circulatory collapse Diseases 0.000 description 2
206010011376 Crepitations Diseases 0.000 description 2
206010011703 Cyanosis Diseases 0.000 description 2
208000004232 Enteritis Diseases 0.000 description 2
208000007766 Kaposi sarcoma Diseases 0.000 description 2
208000009525 Myocarditis Diseases 0.000 description 2
201000007100 Pharyngitis Diseases 0.000 description 2
206010044314 Tracheobronchitis Diseases 0.000 description 2
229960004150 aciclovir Drugs 0.000 description 2
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 2
239000002246 antineoplastic agent Substances 0.000 description 2
208000006673 asthma Diseases 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
229940127089 cytotoxic agent Drugs 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002008 hemorrhagic effect Effects 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
210000003141 lower extremity Anatomy 0.000 description 2
206010025482 malaise Diseases 0.000 description 2
231100000590 oncogenic Toxicity 0.000 description 2
230000002246 oncogenic effect Effects 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
230000029058 respiratory gaseous exchange Effects 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
206010040560 shock Diseases 0.000 description 2
239000000243 solution Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
208000002874 Acne Vulgaris Diseases 0.000 description 1
208000003829 American Hemorrhagic Fever Diseases 0.000 description 1
241000700179 Apodemus Species 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
206010004053 Bacterial toxaemia Diseases 0.000 description 1
208000034200 Bolivian hemorrhagic fever Diseases 0.000 description 1
201000004813 Bronchopneumonia Diseases 0.000 description 1
206010011416 Croup infectious Diseases 0.000 description 1
241000288140 Gruiformes Species 0.000 description 1
208000021727 Hantavirus hemorrhagic fever with renal syndrome Diseases 0.000 description 1
208000032843 Hemorrhage Diseases 0.000 description 1
208000001688 Herpes Genitalis Diseases 0.000 description 1
208000029462 Immunodeficiency disease Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000004895 Lipoproteins Human genes 0.000 description 1
108090001030 Lipoproteins Proteins 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
241000711941 Murine orthopneumovirus Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
206010033799 Paralysis Diseases 0.000 description 1
208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
206010037855 Rash erythematous Diseases 0.000 description 1
206010037868 Rash maculo-papular Diseases 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
208000000389 T-cell leukemia Diseases 0.000 description 1
208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
208000013222 Toxemia Diseases 0.000 description 1
206010000496 acne Diseases 0.000 description 1
201000009628 adenosine deaminase deficiency Diseases 0.000 description 1
230000019552 anatomical structure morphogenesis Effects 0.000 description 1
208000022531 anorexia Diseases 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000002775 capsule Substances 0.000 description 1
231100000504 carcinogenesis Toxicity 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000010307 cell transformation Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
239000006071 cream Substances 0.000 description 1
201000010549 croup Diseases 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
230000010460 detection of virus Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000006260 foam Substances 0.000 description 1
201000004946 genital herpes Diseases 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000007813 immunodeficiency Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
230000003902 lesion Effects 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
208000012965 maculopapular rash Diseases 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
230000010309 neoplastic transformation Effects 0.000 description 1
239000002674 ointment Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000000079 pharmacotherapeutic effect Effects 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
210000005267 prostate cell Anatomy 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
206010037833 rales Diseases 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000036387 respiratory rate Effects 0.000 description 1
208000030925 respiratory syncytial virus infectious disease Diseases 0.000 description 1
230000028327 secretion Effects 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
208000002491 severe combined immunodeficiency Diseases 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
241000894007 species Species 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000013518 transcription Methods 0.000 description 1
230000035897 transcription Effects 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
230000004580 weight loss Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/056—Triazole or tetrazole radicals

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Virology (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

LU85854A 1984-10-29 1985-04-17 Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1,2,4-triazole-3-carboxamide LU85854A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US66625284A	1984-10-29	1984-10-29
US66625284		1984-10-29

Publications (1)

Publication Number	Publication Date
LU85854A1 true LU85854A1 (fr)	1985-12-16

Family

ID=24673430

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU85854A LU85854A1 (fr)	1984-10-29	1985-04-17	Procede de traitement medical de maladies virales utilisant le 1-beta-d-ribofurannosyl-1,2,4-triazole-3-carboxamide

Country Status (18)

Country	Link
EP (3)	EP0383361A3 (de)
JP (1)	JPH0713019B2 (de)
KR (1)	KR860003018A (de)
AT (1)	ATE204173T1 (de)
AU (1)	AU584333B2 (de)
BE (1)	BE902199A (de)
CA (1)	CA1261265A (de)
DD (1)	DD261094A5 (de)
DE (3)	DE3588232T2 (de)
ES (1)	ES8704962A1 (de)
FR (1)	FR2572286B1 (de)
GB (1)	GB2166050B (de)
LU (1)	LU85854A1 (de)
NL (1)	NL300083I1 (de)
NZ (1)	NZ212510A (de)
PH (1)	PH22534A (de)
PT (1)	PT81387B (de)
ZA (1)	ZA858237B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1987003903A1 (en) *	1985-12-23	1987-07-02	Fred Hutchinson Cancer Research Center	Regulating retroviral replication, infection, and pathogenesis
JP2792246B2 (ja) *	1991-01-31	1998-09-03	信越半導体株式会社	単結晶棒クランプ位置決め治具及びこれを用いた単結晶棒クランプ位置決め方法
CA2357735A1 (en) *	1999-01-29	2000-08-03	Icn Pharmaceuticals, Inc.	Modulation of immune response by ribavirin
US6720000B2 (en)	2001-03-19	2004-04-13	Three Rivers Pharmaceutical, Llc	Process for producing wet ribavirin pellets
US7132453B2 (en) *	2002-03-15	2006-11-07	Vanderbilt University	Method of using prostacyclin to treat respiratory syncytial virus infections
US7538094B2 (en)	2002-09-19	2009-05-26	Three Rivers Pharmacueticals, Llc	Composition containing ribavirin and use thereof
WO2015197549A1 (en)	2014-06-23	2015-12-30	Sanovel Ilac Sanayi Ve Ticaret A.S.	A novel pharmaceutical composition of sofosbuvir and ribavirin
EP2959901A1 (de)	2014-06-23	2015-12-30	Sanovel Ilac Sanayi ve Ticaret A.S.	Pharmazeutische kombinationen aus sofosbuvir und ribavirin
EP2959891A1 (de)	2014-06-23	2015-12-30	Sanovel Ilac Sanayi ve Ticaret A.S.	Pharmazeutische zusammensetzungen aus sofosbuvir und ribavirin mit modifizierter freisetzung
JP2018076280A (ja) *	2016-10-28	2018-05-17	国立大学法人大分大学	ジカウイルス感染症治療用医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4211771A (en) *	1971-06-01	1980-07-08	Robins Ronald K	Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
US3798209A (en) *	1971-06-01	1974-03-19	Icn Pharmaceuticals	1,2,4-triazole nucleosides
US3927216A (en) *	1971-06-01	1975-12-16	Icn Pharmaceuticals	1,2,4-Triazol E-3-carboxamides for inhibiting virus infections
AR205339A1 (es) *	1973-03-12	1976-04-30	Icn Pharmaceuticals	Sintesis de 1,2,4-triazolo-3-carboxamidas utiles como agentes antivirales
WO1983003383A1 (en) *	1982-03-29	1983-10-13	Liposome Co Inc	Stable plurilamellar vesicles

1985
- 1985-04-15 BE BE0/214849A patent/BE902199A/fr not_active IP Right Cessation
- 1985-04-16 AT AT94118300T patent/ATE204173T1/de active
- 1985-04-16 EP EP19900105678 patent/EP0383361A3/de not_active Withdrawn
- 1985-04-16 EP EP94118300A patent/EP0643970B1/de not_active Revoked
- 1985-04-16 DE DE3588232T patent/DE3588232T2/de not_active Expired - Lifetime
- 1985-04-16 GB GB8509689A patent/GB2166050B/en not_active Expired
- 1985-04-16 DE DE2002199005 patent/DE10299005I2/de active Active
- 1985-04-16 EP EP85302644A patent/EP0181050A3/de not_active Withdrawn
- 1985-04-16 DE DE198585302644T patent/DE181050T1/de active Pending
- 1985-04-17 LU LU85854A patent/LU85854A1/fr unknown
- 1985-04-30 AU AU41807/85A patent/AU584333B2/en not_active Expired
- 1985-05-07 CA CA000480878A patent/CA1261265A/en not_active Expired
- 1985-05-16 PH PH32282A patent/PH22534A/en unknown
- 1985-05-30 KR KR1019850003752A patent/KR860003018A/ko not_active Ceased
- 1985-05-30 FR FR858508143A patent/FR2572286B1/fr not_active Expired - Fee Related
- 1985-06-05 JP JP60122351A patent/JPH0713019B2/ja not_active Expired - Fee Related
- 1985-06-21 NZ NZ212510A patent/NZ212510A/xx unknown
- 1985-10-09 DD DD85281565A patent/DD261094A5/de active Search and Examination
- 1985-10-28 PT PT81387A patent/PT81387B/pt active IP Right Revival
- 1985-10-28 ZA ZA858237A patent/ZA858237B/xx unknown
- 1985-10-29 ES ES548303A patent/ES8704962A1/es not_active Expired
2002
- 2002-02-14 NL NL300083C patent/NL300083I1/nl unknown

Also Published As

Publication number	Publication date
DE181050T1 (de)	1986-12-18
PT81387B (pt)	1987-11-11
DE10299005I1 (de)	2002-05-08
NZ212510A (en)	1989-04-26
EP0181050A3 (de)	1987-10-21
DE3588232T2 (de)	2002-06-13
ZA858237B (en)	1988-02-24
ES8704962A1 (es)	1987-04-16
ES548303A0 (es)	1987-04-16
EP0383361A2 (de)	1990-08-22
NL300083I1 (nl)	2002-05-01
EP0643970A3 (de)	1997-07-09
GB2166050A (en)	1986-04-30
EP0643970B1 (de)	2001-08-16
KR860003018A (ko)	1986-05-19
FR2572286A1 (fr)	1986-05-02
PT81387A (en)	1985-11-01
JPH0713019B2 (ja)	1995-02-15
FR2572286B1 (fr)	1990-03-23
HK1010985A1 (en)	1999-07-02
GB8509689D0 (en)	1985-05-22
EP0643970A2 (de)	1995-03-22
EP0181050A2 (de)	1986-05-14
EP0383361A3 (de)	1993-06-16
JPS61109723A (ja)	1986-05-28
DE3588232D1 (de)	2001-09-20
CA1261265A (en)	1989-09-26
BE902199A (fr)	1985-07-31
DE10299005I2 (de)	2004-07-01
AU584333B2 (en)	1989-05-25
PH22534A (en)	1988-10-17
ATE204173T1 (de)	2001-09-15
AU4180785A (en)	1986-05-08
DD261094A5 (de)	1988-10-19
GB2166050B (en)	1989-08-16

Publication	Publication Date	Title
EP3528835B1 (de)	2021-03-03	Antivirale zusammensetzungen zur behandlung von infektionen im zusammenhang mit coronaviren
FR2633182A1 (fr)	1989-12-29	Composition pharmaceutique anticancereuse et methode d'utilisation de l'invention
FR3136962A1 (fr)	2023-12-29	Vaccin contre le coronavirus
Korba et al.	1996	Liver‐targeted antiviral nucleosides: enhanced antiviral activity of phosphatidyl‐dideoxyguanosine versus dideoxyguanosine in woodchuck hepatitis virus infection in vivo
FR2572286A1 (fr)	1986-05-02	Utilisation du 1-b-d-ribofuranosyl-1,2,4-triazole-3-carboxamide pour le traitement de maladies virales chez l'homme
JP2899292B2 (ja)	1999-06-02	Ｂ型肝炎の抗ウイルス剤による治療方法
CA2286126C (en)	2003-08-12	Pharmaceutical compositions
Child et al.	1991	Canadian multicenter azidothymidine trial: AZT pharmacokinetics
CN102755355B (zh)	2014-05-21	抗a型流感病毒或肠病毒的药物组合物
WO2021181044A1 (fr)	2021-09-16	Composition comprenant du diltiazem pour traiter l'infection virale par les virus sars-cov-2
JPH10504279A (ja)	1998-04-28	ウイルス感染症及び場合により炎症の予防及び／又は治療用医薬組成物並びにそれらの治療方法
EP4291217B1 (de)	2026-04-01	Therapeutische zusammensetzung basierend auf neurolaena blätter zur hemmung der dhodh und behandlung von rna virus infektionen
CN106432226B (zh)	2019-08-30	1H-咪唑并[4,5-c]喹啉-4-胺类及其相关化合物的前药
FR2464072A1 (fr)	1981-03-06	Medicament antiviral renfermant de la (b-d-arabinofurannosyl)-1 thymine
JP2000516962A (ja)	2000-12-19	ライノウイルス感染症の治療方法
EP0362359A1 (de)	1990-04-11	Antiviren-zubereitung, enthaltend aromatische polycyclische dione und nukleosidanaloge und verfahren zur behandlung von retrovireninfektionen
WO2018178594A1 (fr)	2018-10-04	Prévention d'une infection par le virus respiratoire syncytial dans les voies respiratoires supérieures
JPH07179354A (ja)	1995-07-18	抗ウイルス剤
JP2002511862A (ja)	2002-04-16	ウイルス性および微生物性感染ならびに消耗性症候群の治療に用いる薬剤供給装置および方法
WO1989009055A1 (en)	1989-10-05	Antiviral composition containing aromatic polycyclic diones and nucleoside analogs and method for treating retrovirus infections
EP0004214A1 (de)	1979-09-19	Pharmazeutische Präparate enthaltend ein bakterielles Enzym
JPH02504283A (ja)	1990-12-06	芳香族多環式ジオン化合物とヌクレオシド類似化合物とを含む抗ウイルス性組成物及びレトロウイルス感染を治療するための方法
MXPA01009076A (en)	2002-05-09	Synergistic inhibition of viral replication by long-chain hydrocarbons and nucleoside analogs
Bogger-Goren et al.	1980	Antiviral agents: An update—Part I
MXPA99008690A (en)	2000-01-01	Pharmaceutical compositions